Ixazomib maintenance for the treatment of light chain AL amyloidosis
To the EditorsIn immunoglobulin light chain (AL) amyloidosis, plasma cell disease burden at diagnosis is a key prognostic factor [1]. When patients have >10% clonal bone marrow plasma cells (BMPCs)...
Authors
- Heather Jolie Landau (ORCID: https://orcid.org/0000-0002-3152-1189)
- Caitlin Sarubbi
- Raymond L. Comenzo (ORCID: https://orcid.org/0000-0002-6255-5824)
- Maya Levinson
- Grace B. Gallagher (ORCID: https://orcid.org/0009-0004-9277-5002)
- Mithat Gönen (ORCID: https://orcid.org/0000-0001-8683-8477)
- Hani Hassoun (ORCID: https://orcid.org/0000-0002-2036-1749)
- Sham Mailankody (ORCID: https://orcid.org/0000-0002-2815-9561)
- Eugène Brailovski (ORCID: https://orcid.org/0000-0002-7234-3278)
- Jessica R. Chapman (ORCID: https://orcid.org/0000-0002-4080-8667)
- Theresa Fogaren
Institutions
- Tufts Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Amyloid
- Published
- 2026-10-29
- DOI
- https://doi.org/10.1080/13506129.2026.2740037
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00